• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Pacific Biometrics' Chief Scientific Officer, Elizabeth Leary, PhD, Has Co-Authored the BONES Study Recently Published in the December 2007 Issue of The Journal of Clinical Endocrinology &Amp; Metabolism

Posted on: Tuesday, 22 January 2008, 15:00 CST

Elizabeth Leary, PhD, the Chief Scientific Officer and co-founder of Pacific Biometrics, Inc. (OTCBB: PBME) ("PBI"), has recently been published in the December 2007 issue of The Journal of Clinical Endocrinology & Metabolism. Dr. Leary co-authored the article along with international opinion leaders and researchers in the study of osteoporosis and related musculoskeletal diseases. The study entitled, "Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial," was designed to evaluate whether or not the most widely prescribed medication used for lowering high cholesterol, atorvastatin (Lipitor(R), made by Pfizer), had an effect on bone mineral density (BMD) or biomarkers indicative of bone turnover. While atorvastatin has proven to be effective in improving clinical outcomes in patients with high cholesterol, the authors concluded that the therapeutic doses of the drug "had no effect on bone mineral density or biochemical indices of bone metabolism in this study, suggesting that such oral agents are not useful in the prevention or treatment of osteoporosis."

"This study is another example of PBI's preeminent position in providing specialty lab testing for clinical drug development in the fields of dyslipidemia and musculoskeletal disorders," commented Mario Ehlers, MD, PhD, PBI's Chief Medical Officer. "This study required an unusual combination of expertise in both lipid and bone metabolism, and I believe PBI is one of the few specialty central labs in the world with an established reputation in both areas. We are very pleased to have performed the efficacy testing for this trial and to have contributed to this important publication."

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.

For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including, but not limited to, the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB for the year ended June 30, 2007 and our report on Form 10-QSB for the quarter ended September 30, 2007).

 Contacts:  Pacific Biometrics, Inc. Ron Helm CEO (206) 298-0068  Kari Charbonnel (206) 298-0068  

SOURCE: Pacific Biometrics, Inc.

Source: MARKET WIRE

More News in this Category